OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Revolutionary technology will further boost OneSource’s scientific services offerings
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Subscribe To Our Newsletter & Stay Updated
